Alterity Therapeutics (ATHE) Restructuring Costs (2014 - 2025)

Alterity Therapeutics' Restructuring Costs history runs 11 years deep, the most recent figure standing at $300347.2 for Q4 2025.

• On a quarterly basis, Restructuring Costs rose 1.98% year-over-year to $300347.2 in Q4 2025; TTM through Dec 2025 was $880752.6, a 19.17% increase from a year earlier, with the FY2024 full-year figure at $520.9 billion, up 70.45% from the prior year.
• Restructuring Costs advanced to $300347.2 in Q4 2025 per ATHE's latest filing, from $294528.3 in the prior quarter.
• Across five years, Restructuring Costs topped out at $300347.2 in Q4 2025 and bottomed at $126118.3 in Q4 2023.
• The 5-year median for Restructuring Costs is $159758.8 (2022), against an average of $207880.5.
• Across the five-year window, Restructuring Costs decreased 21.06% in 2023 and surged 133.53% in 2024, its largest moves.
• Year by year, Restructuring Costs stood at $158650.0 in 2021, then increased by 0.7% to $159758.8 in 2022, then dropped by 21.06% to $126118.3 in 2023, then jumped by 133.53% to $294528.3 in 2024, then advanced by 1.98% to $300347.2 in 2025.
• Per Business Quant, the three latest ATHE Restructuring Costs figures stand at $300347.2 (Q4 2025), $294528.3 (Q4 2024), and $126118.3 (Q4 2023).